[1]
Gotto, G., Drachenberg, D.E., Chin, J., Casey, R., Fradet, V., Sabbagh, R., Shayegan, B., Rendon, R.A., Danielson, B., Camacho, F., Zardan, A., Plante, R., Hew, H., Chan, K. and Feifer, A. 2020. Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. Canadian Urological Association Journal. 14, 12 (Jun. 2020), E616-20. DOI:https://doi.org/10.5489/cuaj.6388.